WO2005105764A1 - Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof - Google Patents

Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof Download PDF

Info

Publication number
WO2005105764A1
WO2005105764A1 PCT/EP2005/003607 EP2005003607W WO2005105764A1 WO 2005105764 A1 WO2005105764 A1 WO 2005105764A1 EP 2005003607 W EP2005003607 W EP 2005003607W WO 2005105764 A1 WO2005105764 A1 WO 2005105764A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
radical
membered monocyclic
unsaturated
saturated
Prior art date
Application number
PCT/EP2005/003607
Other languages
French (fr)
Inventor
Jean Jacques Zeiller
Hervé Dumas
Valérie Guyard-Dangremont
Isabelle Berard
Francis Contard
Daniel Guerrier
Gérard Ferrand
Yves Bonhomme
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to DK05729043.9T priority Critical patent/DK1742927T3/en
Priority to SI200531318T priority patent/SI1742927T1/en
Priority to CA2565184A priority patent/CA2565184C/en
Priority to AT05729043T priority patent/ATE503749T1/en
Priority to US11/579,362 priority patent/US7678831B2/en
Priority to DE602005027194T priority patent/DE602005027194D1/en
Priority to AU2005238143A priority patent/AU2005238143B2/en
Priority to JP2007511903A priority patent/JP5295560B2/en
Priority to EP05729043A priority patent/EP1742927B1/en
Priority to PL05729043T priority patent/PL1742927T3/en
Publication of WO2005105764A1 publication Critical patent/WO2005105764A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
    • C07D311/54—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 substituted in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • Butanoic acid derivatives processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
  • the present invention relates to 4-substituted butanoic acid derivatives which can be used in the treatment of dyslipidaemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them, and to processes for the preparation of these compounds.
  • the invention also relates to the use of these compounds for the preparation of medicaments for the treatment of dyslipidaemia, atherosclerosis and diabetes.
  • cardiovascular disease remains one of the major diseases and the main cause of death.
  • About one third of men develop a major cardiovascular disease before the age of 60, with women showing a lower risk (ratio of 1 to 10).
  • vascular diseases such as coronary disease, strokes, restenosis and peripheral vascular disease remain the prime cause of death and handicap worldwide. Whereas the diet and lifestyle can accelerate the development of cardiovascular diseases, a genetic predisposition leading to dyslipidaemia is a significant factor in cardiovascular accidents and death.
  • the development of atherosclerosis appears to be linked mainly to dyslipidaemia, which means abnormal levels of lipoproteins in the blood plasma. This dysfunction is particularly evident in coronary disease, diabetes and obesity.
  • the concept intended to explain the development of atherosclerosis was mainly focused on the metabolism of cholesterol and on the metabolism of triglycerides. However, since the studies of Randle et al.
  • a novel concept has been proposed: a glucose-fatty acid cycle or Randle cycle, which describes the regulation of the equilibrium between the metabolism of lipids in terms of triglycerides and cholesterol, and the oxygenation of glucose.
  • the inventors have developed a novel programme, the aim of which is to find novel compounds acting simultaneously on lipid metabolism and glucose metabolism.
  • Fibrates are well-known therapeutic agents with a mechanism of action via the "Peroxisome Proliferator Activated Receptors" (PPARs). These receptors are the main regulators of lipid metabolism in the liver (PPAR ⁇ isoform).
  • PPARs Peroxisome Proliferator Activated Receptors
  • PPAR ⁇ Peroxisome Proliferator Activated Receptors
  • thiazolidinediones have been described as powerful hypoglycaemiant agents in man and animals. It has been reported that thiazolidinediones are powerful selective activators of another isoform of
  • PPARs PPARy (Lehmann et al., J. Biol. Chem., (1995), 270, 12953-12956).
  • the inventors have discovered a novel class of compounds that are powerful activators of the PPAR ⁇ and PPARy isoforms. As a result of this activity, these compounds have a substantial hypolipidaemiant and hypoglycaemiant effect. More specifically, the invention relates to compounds derived from butanoic acid, of the formula (I) below:
  • R is chosen from a hydrogen atom and a C 1 -C 10 alkyl radical
  • R 1 and R 2 which may be identical or different, are chosen such that: A.- either: R 1 is chosen from: • a (C 6 -Cis)aryl radical bearing from two to five identical or different substituents G; • a (C 6 -C ⁇ 8 )aryl radical bearing a substituent G, itself comprising an optionally substituted (C 6 -C ⁇ 8 )aryl radical and/or a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; • an optionally substituted (C 6 -C ⁇ 8 )aryl radical, fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (
  • Such compounds have been disclosed in patents US 3 378 582 and FR 1 476 525, which describe certain alkanoic acids bearing an aryl substituent, with hypocholesterolaemic activity.
  • the acids that can be used to form the salts of the compounds of the formula (I) are mineral or organic acids.
  • the resulting salts are, for example, the hydrochlorides, hydrobromides, sulfates, hydrogen sulfates, dihydrogen phosphates, citrates, maleates, fumarates, 2-naphthalenesulfonates and para-toluenesulfonates.
  • the bases that can be used to form the salts of the compounds of the formula (I) are mineral or organic bases.
  • the resulting salts are, for example, the salts formed with metals and especially alkali metals, alkaline- earth metals and transition metals (such as sodium, potassium, calcium, magnesium or aluminium), or with bases, for instance ammonia or secondary or tertiary amines (such as diethylamine, triethylamine, piperidine, piperazine or morpholine) or with basic amino acids, or with osamines (such as meglumine) or with amino alcohols (such as 3-aminobutanol and 2- aminoethanol).
  • the invention especially covers the pharmaceutically acceptable salts, but also the salts that allow a suitable separation or crystallization of the compounds of the formula (I), such as the salts obtained with chiral amines.
  • the invention also covers the stereoisomers of the compounds of the formula (I), and also mixtures of stereoisomers in all proportions.
  • the compounds of the formula (I) above also include the prodrugs of these compounds.
  • prodrugs means compounds which, once administered to the patient, are chemically and/or biologically converted by the live organism into compounds of the formula (I).
  • aryl radical means a monocyclic or polycyclic carbocyclic aromatic radical preferably containing from 6 to 18 carbon atoms. Aryl radicals that may be mentioned include phenyl, naphthyl, anthryl and phenanthryl radicals.
  • alkyl means a linear or branched hydrocarbon-based chain containing from 1 to 10 carbon atoms and better still from 1 to 6 carbon atoms, for example from 1 to 4 carbon atoms.
  • alkyl radicals are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, 2-methylbutyl, 1-ethylpropyl, hexyl, isohexyl, neohexyl, 1-methylpentyl, 3-methylpentyl, 1 ,1-dimethylbutyl, 1 ,3- dimethylbutyl, 1 -ethylbutyl, 1-methyl-1-ethylpropyl, heptyl, 1-methylhexyl, 1- propylbutyl, 4,4-dimethylpentyl, octyl, 1-methylh
  • the heterocyclic radicals are monocyclic or polycyclic radicals comprising hetero atoms generally chosen from O, S and N, optionally in oxidized form (in the case of S and N).
  • at least one of the monocycles constituting the heterocycle comprises from 1 to 4 endocyclic hetero atoms and better still from 1 to 3 hetero atoms.
  • the polycyclic heterocyclic nucleus consists of one or more monocycles, each of which is 5- to 8-membered.
  • Examples of 5- to 8-membered monocyclic aromatic heterocyclic groups are heteroaryls, such as pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isoxazole, isothiazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadiazole, triazole and thiadiazole.
  • Preferred heteroaryl radicals that may be mentioned include pyridyl, pyrimidinyl, triazolyl, thiadiazolyl, oxazolyl, thiazolyl and thienyl radicals.
  • heterocyclic groups examples of 5- to 8- membered monocyclic aromatic heterocyclic groups containing one or more hetero atoms chosen from oxygen and sulfur are heteroaryls, such as furan and thiophene.
  • heteroaryls such as furan and thiophene.
  • 6- to 8-membered monocyclic aromatic heterocyclic groups containing at least one nitrogen atom as heterocycle are pyridine, thiazines (including thiadiazines and dithiazines), triazines, pyridazine, pyrazine and pyrimidine.
  • Preferred heteroaryl radicals that may be mentioned include pyridyl, pyrimidinyl, thiadiazolyl and thienyl radicals.
  • the saturated or unsaturated heterocyclic radicals are heterocyclic groups bearing no unsaturation, or comprising one or more unsaturations derived from the aromatic heterocyclic groups defined above, respectively. Included along with those are pyrans, thiopyrans, morpholine and thiomorpholine.
  • C 2 -C 10 alkenyl radical means an aliphatic hydrocarbon- based radical containing one or more unsaturations of ethylenic type, preferably 1 to 3 ethylenic unsaturations.
  • the alkenyl radical is optionally substituted, preferably with one or more radicals chosen from carboxyl, (C ⁇ -C 6 )alkoxycarbony! and phenyl.
  • the aryl and heterocyclic radicals may be optionally substituted by one or more of the following radicals G: trifluoromethyl; styryl; a halogen atom; a monocyclic, bicyclic or tricyclic aromatic heterocyclic radical comprising one or more hetero atoms chosen from O, N and S; and optionally substituted by one or more radicals T as defined below; a group Het-CO-, in which Het represents an aromatic heterocyclic radical as defined above optionally substituted by one or more radicals T; a C C ⁇ alkylenediyl chain; a C ⁇ -C 6 alkylenedioxy chain; nitro; cyano; (C ⁇ -C 10 )alkyl; (C ⁇ -C- ⁇ o)alkylcarbonyl; (Ci-Cio)al
  • the monocyclic, bicyclic or tricyclic aromatic heterocyclic radicals preferably comprise one or more hetero atoms generally chosen from 0, S and N, optionally in oxidized form (in the case of S and N).
  • at least one of the monocycles constituting the heterocycle comprises from 1 to 4 endocyclic hetero atoms and better still from 1 to 3 hetero atoms.
  • the heterocycle consists of one or more monocycles, each of which is 5- to 8-membered.
  • Examples of 5- to 8-membered monocyclic heteroaryls are especially pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isoxazole, isothiazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadiazole, triazole and thiadiazole.
  • bicyclic heteroaryls in which each monocycles is 5- to 8- membered are chosen from indolizine, indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, benzothiazole, benzofurazane, benzothiofurazane, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridines, pyrazolotriazine (such as pyrazolo- 1 ,3,4-triazine), pyrazolopyrimidine and pteridine.
  • heteroaryl radicals that may be mentioned include quinolyl, pyridyl, benzothiazolyl and triazolyl radicals.
  • the tricyclic heteroaryls in which each monocycle is 5- to 8-membered are chosen, for example, from acridine, phenazine and carbazole.
  • alkylenediyl chain means a divalent radical of linear or branched aliphatic hydrocarbon-based type derived from the alkyl groups defined above by stripping out a hydrogen atom.
  • alkylenediyl chains are chains -(CH 2 ) k -, in which k represents an integer chosen from 2, 3, 4, 5 and 6 and >C(CH 3 ) 2 and -CH 2 -C(CH 3 ) 2 -CH 2 - chains.
  • the alkylenedioxy chains denote -O-Alk-0- chains, in which Alk represents linear or branched alkylene, it being understood that alkylene is as defined above for alkylenediyl.
  • Preferred meanings of -O-Alk-O- are, for example, -0-C(CH 3 ) 2 -O or -0-CH 2 -CH 2 -O-.
  • alkenylene defines an unsaturated alkylene chain containing one or more ethylenic unsaturations, preferably one to three ethylenic unsaturations.
  • C 3 -C 10 cycloalkyl radicals are especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or cyclodecyl radicals.
  • Saturated or unsaturated, monocyclic 5- to 8-membered heterocycles are saturated, or unsaturated, derivatives of aromatic heterocycles.
  • alkynyl means an aliphatic hydrocarbon-based group containing one or more unsaturations of acetylenic type. A preferred example is -CsC-.
  • R represents a hydrogen atom
  • R 1 and R 2 being as defined previously, the optical isomers thereof, and also the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R 2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R 1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical.
  • R 1 represents a (C 6 -C-
  • R 2 is chosen from: • a (C 6 -C ⁇ 8 )aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; R being as defined above, the optical isomers thereof, and
  • R 1 represents an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; or alternatively fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and R 2 is chosen from: • a (C 6 -Ci 8 )aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered
  • R 1 represents a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S
  • R 2 is chosen from: • a (C 6 -C ⁇ s)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
  • R 1 represents a (C 6 -C ⁇ 8 )aryl radical bearing from two to five identical or different substituents G; and R 2 is chosen from: • a (C 6 -C 18 )aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
  • R 1 represents a (C 6 -C ⁇ 8 )aryl radical bearing from two to five identical or different substituents G
  • R 2 is chosen from: • a (C 6 -C 18 )aryl radical, which is optionally substituted and/or
  • R 2 represents a (C 6 -C ⁇ 8 )aryl radical substituted by a (C6-C ⁇ 8 )aryl radical, which is itself optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and R 1 is chosen from: • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated, 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the
  • R 2 represents an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and R 1 is chosen from: • an optionally substituted (C 6 -C 18 )aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and
  • R 2 represents an optionally substituted biphenyl radical
  • R 1 is chosen from: • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with
  • R 2 represents an optionally substituted halogenated biphenyl radical, preferably an optionally substituted 4'-halogenated biphenyl radical
  • R 1 is chosen from: • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C 6 -C ⁇ 8 )aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur;
  • the compounds that are also preferred are those of the general formula (I) for which, when R 1 represents a substituted (C 6 -C ⁇ 0 )aryl radical, the aryl nucleus is substituted by one or more radicals G chosen from: trifluoromethyl; a halogen atom; styryl; a monocyclic, bicyclic or tricyclic aromatic heterocyclic radical comprising one or more hetero atoms chosen from O, N and S; and optionally substituted by one or more radicals T as defined below; a group Het-CO-, in which Het represents an aromatic heterocyclic group as defined above, optionally substituted by one or more radicals T; a C ⁇ -C 6 alkylenediyl chain; a Ci-C ⁇ alkylenedioxy chain; amino; nitro; cyano; (C1-C10)- alkyl radical; (C 2 -C 6 )alkynyl radical; (C ⁇ -C ⁇ o)alkylcarbonyl radical; (C ⁇
  • the preferred compounds are those of the formula (I) chosen from: • (2S)-2-[4-(5-chlorothien-2-yl)phenoxy]-4-phenylbutanoic acid; • 2- ⁇ 2-[3-(4-chlorophenyl)acryloyl]-4-methylphenoxy ⁇ -4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-2-yl)phenoxy]-4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-3-yl)phenoxy)-4-phenylbutanoic acid; • 4-(2-fluorophenyl)-2-[4-(2-methylthiazol-4-yl)phenoxy]butanoic acid; • 4-(4'-chlorobiphenyl-4-yl)-2-(4-nitrophenoxy)butanoic acid; • 4-(4-fluorophenyl)-2-[4-(2-methylthio
  • compositions comprising a pharmaceutically effective amount of at least one compound of the formula (I) as defined above in combination with one or more pharmaceutically acceptable vehicles.
  • These compositions can be administered orally in the form of tablets, gel capsules or granules with immediate release or controlled release, intravenously in the form of an injectable solution, transdermally in the form of an adhesive transdermal device, or locally in the form of a solution, cream or gel.
  • a solid composition for oral administration is prepared by adding to the active principle a filler and, where appropriate, a binder, a disintegrating agent, a lubricant, a colorant or a flavour enhancer, and by forming the mixture into a tablet, a coated tablet, a granule, a powder or a capsule.
  • fillers include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide
  • binders include poly(vinyl alcohol), poly(vinyl ether), ethylcellulose, methylcellulose, acacia, gum tragacanth, gelatine, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin.
  • lubricants include magnesium stearate, talc, polyethylene glycol, silica and hardened plant oils. The colorant may be any of those permitted for used in medicaments.
  • flavour enhancers examples include cocoa powder, mint in herb form, aromatic powder, mint in oil form, borneol and cinnamon powder.
  • the tablet or granule can be suitably coated with sugar, gelatine or the like.
  • An injectable form comprising the compound of the present invention as active principle is prepared, where appropriate, by mixing the said compound with a pH regulator, a buffer agent, a suspension agent, a solubilizer, a stabilizer, an isotonic agent and/or a preserving agent, and by converting the mixture into a form for intravenous, subcutaneous or intramuscular injection, according to a standard process. Where appropriate, the injectable form obtained can be freeze-dried via a standard process.
  • suspension agents include methylcellulose, polysorbate 80, hydroxyethylcellulose, acacia, powdered gum tragacanth, sodium carboxymethylcellulose and polyethoxylated sorbitan monolaurate.
  • solubilizers include castor oil solidified with polyoxyethylene, polysorbate 80, nicotinamide, polyethoxylated sorbitan monolaurate and the ethyl ester of castor oil fatty acid.
  • the stabilizer encompasses sodium sulfite, sodium metasulfite and ether
  • the preserving agent encompasses methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol.
  • the present invention also relates to the use of a compound of the formula (I) of the invention for the preparation of a medicament for the prevention of or treating dyslipidaemia, atherosclerosis and diabetes.
  • the effective administration doses and posologies of the compounds of the invention, intended for the prevention or treatment of a disease, disorder or condition caused by or associated with modulation of PPAR activity depends on a large number of factors, for example on the nature of the inhibitor, the size of the patient, the aim of the desired treatment, the nature of the pathology to be treated, the specific pharmaceutical composition used and the observations and the conclusions of the treating physician.
  • a possible suitable dosage of the compounds of the formula (I) is between about 0.1 mg/kg and about 100 mg/kg of body weight per day, preferably between about 0.5 mg/kg and about 50 mg/kg of body weight per day, more preferably between about 1 mg/kg and about 10 mg/kg of body weight per day and more preferably between about 2 mg/kg and about 5 mg/kg of body weight per day of active material.
  • suitable dosages of the compounds of the formula (I) will be between about 1-10 mg and 1000-10 000 mg per day, preferably between about 5-50 mg and 500-5000 mg per day, more preferably between about 10.0-100.0 mg and 100.0-1000.0 mg per day and even more preferably between about 20.0-200.0 mg and about 50.0-500.0 mg per day of active material comprising a preferred compound. These dosage ranges represent total amounts of active material per day for a given patient.
  • the number of administrations per day at which a dose is administered can vary within wide proportions depending on pharmacokinetic and pharmacological factors, such as the half-life of the active material, which reflects its rate of catabolism and clearance, and also the minimum and optimum levels of the said active material, in blood plasma or in other bodily fluids, which are reached in the patient and which are required for therapeutic efficacy. Many other factors should also be taken into consideration when determining the number of daily administrations and the amount of active material that should be administered in a single dosage intake. Among these other factors, and not the least of which, is the individual response of the patient to be treated.
  • the present invention also relates to a general process for the preparation of the compounds of the formula (I), by reaction of a compound of the formula (II) with an alcohol of the formula R 1 -OH, according to the following reaction scheme: (Aa) : THF / PPh 3 / DIAD / room temp. (Ab) : EtOH / KOH / H 2 0 reflux in which reaction scheme R 1 and R 2 are as defined above for formula (I), R' represents R as defined above, with the exception of hydrogen, the compound (IR-) being the compound of the formula (I) in which R represents a C1-C10 alkyl radical, as defined above, and the compound (I 0 H) being the compound of the formula (I) in which R represents -H.
  • THF means tetrahydrofuran.
  • PPh 3 means triphenylphosphine, DIAD means diisopropyl azodicarboxylate, "room temp.” means room temperature, EtOH is ethanol and KOH is potassium hydroxide.
  • the reaction step (Aa) is preferably performed in a polar aprotic solvent, such as a linear or cyclic ether of the type, such as diethyl ether, di- tert-butyl ether, diisopropyl ether or dimethoxyethane, or alternatively of the type, such as dioxane or tetrahydrofuran, tetrahydrofuran and dimethoxyethane being preferred.
  • a polar aprotic solvent such as a linear or cyclic ether of the type, such as diethyl ether, di- tert-butyl ether, diisopropyl ether or dimethoxyethane, or alternatively
  • the molar ratio of the compound of the formula (II) to the alcohol R 1 -OH ranges between 1 and 1.5, an approximately stoichiometric ratio of between 1 and 1.3 and preferably between 1 and 1.1 being desirable.
  • a coupling agent such as a lower alkyl (i.e. a Ci-C ⁇ alkyl) azodicarboxylate, for example diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD).
  • the coupling agent When it is present in the reaction medium, the coupling agent is incorporated into the medium in a proportion of from 0.9 to 5 molar equivalents and better still in a proportion of from 0.9 to 3 molar equivalents, for example in a proportion of from 0.9 to 2 molar equivalents, relative to the initial amount of compound of the formula (II).
  • a phosphine into the reaction medium, such as triphenylphosphine.
  • the molar ratio of the triphenylphosphine to the compound of the formula (II) is preferably maintained between 0.9 and 5, for example between 0.9 and 3 and especially between 0.9 and 2.
  • the reaction temperature generally ranges between -15°C and 60°C.
  • H can advantageously be obtained by saponification of the corresponding compounds of the formula (l R -).
  • the saponification can be performed via the action of a base, such as a mineral base chosen from lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate and potassium carbonate.
  • a base such as a mineral base chosen from lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate and potassium carbonate.
  • the molar amount of base to be used generally ranges from 1 to 20 equivalents and preferably from 1 to 12 equivalents depending on the strength of the selected base. More particularly, in the case of lithium hydroxide (LiOH), it is preferred to incorporate from 8 to 12 equivalents of base relative to the amount of ester of the formula (I) present in the reaction medium.
  • the reaction is preferably performed in a solvent of polar protic type and preferably in a mixture of lower (C 1 -C 4 ) alkanol and water, such as a mixture of ethanol and water or of methanol and water.
  • the reaction temperature advantageously ranges between 20°C and
  • the compounds of the formula (l G ), which is a special case of the compounds of the formula (I) in which R 1 represents an aryl radical substituted by a radical G as defined above, can be prepared according to the following reaction scheme:
  • R 2 is as defined above for formula (I) ;
  • R' represents R, as defined above, with the exception of hydrogen;
  • R 11 represents R 1 , as defined above, bearing a group that is reactive with the derivative of the formula (IV) and chosen especially from a bromine or iodine atom and a CF 3 S0 3 - radical, bromine and iodine being the preferred reactive groups;
  • - R 12 represents R 11 , in which the group that is reactive with the derivative of the formula (IV) has been substituted by the radical G.
  • the saponification step (Bb) is optional.
  • the compounds of the formulae (IG, RO and (IG, H) form the set of compounds of the formula (IG), which is a special case of the compounds of the formula (I) in which R 1 represents an aryl radical substituted by a radical G.
  • the compounds of the formula (I) in which R 1 represents aryl substituted by a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S, and optionally substituted by one or more radicals T as defined above, or alternatively in which R 1 represents an aryl group optionally substituted by one or more radicals T, can be prepared by reaction of the corresponding compound of the formula (III) defined above with a compound of the formula (IV) defined in the above reaction scheme, in which G represents a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S, and optionally substituted by one or more radicals T as defined above when R 1 , in the final compound, represents aryl substituted by such a heterocyclic group, or alternatively G represents aryl optionally substituted by one or more radicals T when, in the final compound, R 1 represents aryl substituted by an aryl group, which is itself
  • the reaction medium from 1.5 to 5 equivalents and preferably from 1.5 to 3 equivalents of the compound of the formula (IV) are incorporated relative to the amount of compound of the formula (111) present in the reaction medium.
  • This reaction is preferably performed in a polar aprotic solvent in the presence of a palladium 0 complex and a base.
  • a linear or cyclic ether, such as those defined above is more particularly suitable as solvent. Dimethoxyethane is preferred.
  • the base that will be used is any of the mineral bases mentioned above and advantageously sodium carbonate.
  • from 1.5 to 5 equivalents and preferably from 1.5 to 3 equivalents of base, relative to the amount of compound of the formula (III) can be introduced into the reaction medium.
  • the amount of palladium 0 complex used is catalytic.
  • reaction temperature advantageously ranges between 50°C and
  • the compounds of the formula (I) can also be prepared according to a synthetic route using compounds grafted onto resin, for example of Wang bromo type, according to the following reaction scheme:
  • the compound is then detached from the resin, according to standard techniques, for example using trifluoroacetic acid, to give the carboxyiic acid obtained in the final step of the above reaction scheme.
  • This carboxyiic acid is a special case of the compound of the formula (I) in which R represents hydrogen, and can optionally be readily converted into a compound of the formula (I) in which R has the definition indicated previously for all the compounds according to the invention, with the exception of hydrogen, via any method known per se.
  • the operating conditions can vary substantially depending on the various substituents present in the compounds of the formula (I) that it is desired to prepare.
  • optical isomers of the compounds of the formula (I) can be obtained, on the one hand, via standard techniques for separating and/or purifying isomers, known to those skilled in the art, from the racemic mixture of the compound of the formula (I).
  • the optical isomers can also be obtained directly via stereoselective synthesis of an optically active starting compound.
  • the following reaction scheme gives an illustration of an example of a stereoselective synthesis using an optically active starting compound:
  • Example 1 Process for the preparation of methyl 2-[4-(2-methyl-1 ,3- thiazol-4-yl)phenoxy]-4-(4-fluorophenyl)butanoate 6.7 mmol of diisopropyl azodicarboxylate dissolved in 5 ml of toluene are added dropwise over 45 minutes to a suspension, under a nitrogen atmosphere, of 7 mmol of methyl 4-(4-fluorophenyl)-2-hydroxybutanoate, 6.3 mmol of 4-(2-methyl-1 ,3-thiazol-4-yl)phenol and 6.9 mmol of triphenylphosphine in 50 ml of toluene, heated to 54°C ⁇ 3°C.
  • Example 2 Process for the preparation of 2-[4-(2-methyl-1,3-thiazol-4- yl)phenoxy]-4-(4-fluorophenyl)butanoic acid (Example 145 of the table)
  • Example 5 Process for the preparation of (E)-2-[4-(2-ethoxycarbonyl- vinyl)-2-methoxyphenoxy]-4-phenylbutanoic acid (Example 66 of the table)
  • the resin is then washed several times with tetrahydrofuran (THF) (3 x 150 ml, 2 minutes), 1/1 THF/H 2 0 (3 * 150 ml, 2 minutes), methanol (3 x 150 ml, 2 minutes), dichloromethane (3 x 150 ml, 2 minutes) and methanol (3 x 150 ml, 2 minutes).
  • THF tetrahydrofuran
  • the resin is dried under vacuum at 50°C.
  • a solution of ethyl (E)-3-(4-hydroxy-2-methoxy)phenylpent-2-enoate (1 mmol) in dichloromethane (2 ml) is added to grafted resin (150 mg, 0.1 mmol).
  • the cells are plated into 96-well microplates and co-transfected using a commercial reagent with the reporter plasmid (pG5-tk-pGL3) and the expression vector for the chimeric protein (PPAR ⁇ -Gal4 or PPAR ⁇ -Gal4).
  • whole culture medium comprising 10% foetal calf serum
  • the medium is removed and replaced with whole medium comprising the test products (50 ⁇ M final). The products are left in contact with the cells for 18 hours.
  • the cells are then lysed and the luciferase activity is measured using a luminometer.
  • a PPAR activation factor can then be calculated by means of activation of the expression of the reporter gene induced by the product (relative to the control cells that have not received any product).
  • the compound of Example 18 at a concentration of 50 ⁇ M activates the chimeric protein PPAR ⁇ -Gal-4 by a factor of 16, and the chimeric protein PPAR ⁇ -Gal4 by a factor of 41.
  • the luciferase activity measured in the presence of this product is zero.
  • the antidiabetic and hypolipidaemiant activity of the compounds according to the invention was determined orally on db/db mice. 15-week-old db/db mice are treated orally for 15 days with the compound of Example 18 (20 mg/kg/day). Each group studied comprises seven animals. After treatment for 15 days, retro-orbital samples are taken under mild anaesthesia and after fasting for four hours.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the preparation of these compounds. Compounds of formula (I) are activators of PPARα and PPARα isoforms.

Description

Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
The present invention relates to 4-substituted butanoic acid derivatives which can be used in the treatment of dyslipidaemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them, and to processes for the preparation of these compounds. The invention also relates to the use of these compounds for the preparation of medicaments for the treatment of dyslipidaemia, atherosclerosis and diabetes. In most countries, cardiovascular disease remains one of the major diseases and the main cause of death. About one third of men develop a major cardiovascular disease before the age of 60, with women showing a lower risk (ratio of 1 to 10). With advancing years (after the age of 65, women become just as vulnerable to cardiovascular diseases as men), this disease increases even more in scale. Vascular diseases, such as coronary disease, strokes, restenosis and peripheral vascular disease remain the prime cause of death and handicap worldwide. Whereas the diet and lifestyle can accelerate the development of cardiovascular diseases, a genetic predisposition leading to dyslipidaemia is a significant factor in cardiovascular accidents and death. The development of atherosclerosis appears to be linked mainly to dyslipidaemia, which means abnormal levels of lipoproteins in the blood plasma. This dysfunction is particularly evident in coronary disease, diabetes and obesity. The concept intended to explain the development of atherosclerosis was mainly focused on the metabolism of cholesterol and on the metabolism of triglycerides. However, since the studies of Randle et al. (Lancet, 1963, 785-789), a novel concept has been proposed: a glucose-fatty acid cycle or Randle cycle, which describes the regulation of the equilibrium between the metabolism of lipids in terms of triglycerides and cholesterol, and the oxygenation of glucose. Following this concept, the inventors have developed a novel programme, the aim of which is to find novel compounds acting simultaneously on lipid metabolism and glucose metabolism. Fibrates are well-known therapeutic agents with a mechanism of action via the "Peroxisome Proliferator Activated Receptors" (PPARs). These receptors are the main regulators of lipid metabolism in the liver (PPARα isoform). In the last 10 years, thiazolidinediones have been described as powerful hypoglycaemiant agents in man and animals. It has been reported that thiazolidinediones are powerful selective activators of another isoform of
PPARs: PPARy (Lehmann et al., J. Biol. Chem., (1995), 270, 12953-12956). The inventors have discovered a novel class of compounds that are powerful activators of the PPARα and PPARy isoforms. As a result of this activity, these compounds have a substantial hypolipidaemiant and hypoglycaemiant effect. More specifically, the invention relates to compounds derived from butanoic acid, of the formula (I) below:
Figure imgf000003_0001
in which: R is chosen from a hydrogen atom and a C1-C10 alkyl radical; R1 and R2, which may be identical or different, are chosen such that: A.- either: R1 is chosen from: • a (C6-Cis)aryl radical bearing from two to five identical or different substituents G; • a (C6-Cι8)aryl radical bearing a substituent G, itself comprising an optionally substituted (C6-Cι8)aryl radical and/or a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; • an optionally substituted (C6-Cι8)aryl radical, fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical, fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; and, in this case, R2 is chosen from: • a (C6-Cι8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from 0, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; B.- or: R2 is chosen from: • a (C6-Cι8)aryl radical substituted by a (C6-Cι8)aryl radical, which is itself optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and, in this case, R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus bearing at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical. Such compounds have been disclosed in patents US 3 378 582 and FR 1 476 525, which describe certain alkanoic acids bearing an aryl substituent, with hypocholesterolaemic activity. The acids that can be used to form the salts of the compounds of the formula (I) are mineral or organic acids. The resulting salts are, for example, the hydrochlorides, hydrobromides, sulfates, hydrogen sulfates, dihydrogen phosphates, citrates, maleates, fumarates, 2-naphthalenesulfonates and para-toluenesulfonates. The bases that can be used to form the salts of the compounds of the formula (I) are mineral or organic bases. The resulting salts are, for example, the salts formed with metals and especially alkali metals, alkaline- earth metals and transition metals (such as sodium, potassium, calcium, magnesium or aluminium), or with bases, for instance ammonia or secondary or tertiary amines (such as diethylamine, triethylamine, piperidine, piperazine or morpholine) or with basic amino acids, or with osamines (such as meglumine) or with amino alcohols (such as 3-aminobutanol and 2- aminoethanol). The invention especially covers the pharmaceutically acceptable salts, but also the salts that allow a suitable separation or crystallization of the compounds of the formula (I), such as the salts obtained with chiral amines. The invention also covers the stereoisomers of the compounds of the formula (I), and also mixtures of stereoisomers in all proportions. The compounds of the formula (I) above also include the prodrugs of these compounds. The term "prodrugs" means compounds which, once administered to the patient, are chemically and/or biologically converted by the live organism into compounds of the formula (I). According to the invention, the term "aryl radical" means a monocyclic or polycyclic carbocyclic aromatic radical preferably containing from 6 to 18 carbon atoms. Aryl radicals that may be mentioned include phenyl, naphthyl, anthryl and phenanthryl radicals. The term "alkyl" means a linear or branched hydrocarbon-based chain containing from 1 to 10 carbon atoms and better still from 1 to 6 carbon atoms, for example from 1 to 4 carbon atoms. Examples of alkyl radicals are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, 2-methylbutyl, 1-ethylpropyl, hexyl, isohexyl, neohexyl, 1-methylpentyl, 3-methylpentyl, 1 ,1-dimethylbutyl, 1 ,3- dimethylbutyl, 1 -ethylbutyl, 1-methyl-1-ethylpropyl, heptyl, 1-methylhexyl, 1- propylbutyl, 4,4-dimethylpentyl, octyl, 1-methylheptyl, 2-methylhexyl, 5,5- dimethylhexyl, nonyl, decyl, 1-methylnonyl, 3,7-dimethyloctyl and 7,7- dimethyloctyl. Unless otherwise mentioned, the heterocyclic radicals are monocyclic or polycyclic radicals comprising hetero atoms generally chosen from O, S and N, optionally in oxidized form (in the case of S and N). Preferably, at least one of the monocycles constituting the heterocycle comprises from 1 to 4 endocyclic hetero atoms and better still from 1 to 3 hetero atoms. According to the invention, the polycyclic heterocyclic nucleus consists of one or more monocycles, each of which is 5- to 8-membered. Examples of 5- to 8-membered monocyclic aromatic heterocyclic groups are heteroaryls, such as pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isoxazole, isothiazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadiazole, triazole and thiadiazole. Preferred heteroaryl radicals that may be mentioned include pyridyl, pyrimidinyl, triazolyl, thiadiazolyl, oxazolyl, thiazolyl and thienyl radicals. Among the heterocyclic groups defined above, examples of 5- to 8- membered monocyclic aromatic heterocyclic groups containing one or more hetero atoms chosen from oxygen and sulfur are heteroaryls, such as furan and thiophene. Examples of 6- to 8-membered monocyclic aromatic heterocyclic groups containing at least one nitrogen atom as heterocycle are pyridine, thiazines (including thiadiazines and dithiazines), triazines, pyridazine, pyrazine and pyrimidine. Preferred heteroaryl radicals that may be mentioned include pyridyl, pyrimidinyl, thiadiazolyl and thienyl radicals. The saturated or unsaturated heterocyclic radicals are heterocyclic groups bearing no unsaturation, or comprising one or more unsaturations derived from the aromatic heterocyclic groups defined above, respectively. Included along with those are pyrans, thiopyrans, morpholine and thiomorpholine. The term "C2-C10 alkenyl radical" means an aliphatic hydrocarbon- based radical containing one or more unsaturations of ethylenic type, preferably 1 to 3 ethylenic unsaturations. Preferred examples of such C2-Cιo alkenyl groups are especially radicals chosen from vinyl and CH2=CH- CH2=CH- groups. The alkenyl radical is optionally substituted, preferably with one or more radicals chosen from carboxyl, (Cι-C6)alkoxycarbony! and phenyl. The aryl and heterocyclic radicals may be optionally substituted by one or more of the following radicals G: trifluoromethyl; styryl; a halogen atom; a monocyclic, bicyclic or tricyclic aromatic heterocyclic radical comprising one or more hetero atoms chosen from O, N and S; and optionally substituted by one or more radicals T as defined below; a group Het-CO-, in which Het represents an aromatic heterocyclic radical as defined above optionally substituted by one or more radicals T; a C Cβ alkylenediyl chain; a Cι-C6 alkylenedioxy chain; nitro; cyano; (Cι-C10)alkyl; (Cι-C-ιo)alkylcarbonyl; (Ci-Cio)alkoxycarbonyl-A-, in which A represents (Ci-Cβ)- alkylene, (C2-C6)alkenylene or a bond; (C3-Cιo)cycloalkyl; trifluoromethoxy; di(Cι-Cιo)alkylamino; (Cι-C10)alkoxy(CrCιo)alkyl; (Cι-C10)alkoxy; (C6-C 8)aryl optionally substituted by one or more radicals T; (C6-Cι8)aryl(Cι-Cιo)a!koxy- (CO)n-, in which n is 0 or 1 and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(CO)n-, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; (C6-Ci8)arylthio, in which aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(Cι-Cι0)alkyl- (CO)n-, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; a saturated or unsaturated, monocyclic 5- to 8-membered heterocycle comprising one or more hetero atoms chosen from O, N and S, optionally substituted by one or more radicals T; (C6-Ci8)arylcarbonyl optionally substituted by one or more radicals T; (C6-Cι8)arylcarbonyl-B-(CO)n-, in which n is 0 or 1; B represents (CrCβ)alkylene or (C2-C6)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cιs)aryl-C-(CO)n-, in which n is 0 or 1, C represents (CrC6)alkylene or (C2-Ce)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryl fused to a saturated or unsaturated heterocycle as defined above, optionally substituted by one or more radicals T; (C2-Cιo)alkynyl; T is chosen from a halogen atom; (C6-C18)aryl; (Cι-C6)alkyl; (C C6)alkoxy; (Cι-C6)alkoxy(C6-C18)aryl; nitro; carboxyl; (Cι-Ce)alkoxycarboxyl; and T may represent oxo in the case where it substitutes a saturated or unsaturated heterocycle; or T represents (Cι-C6)- alkoxycarbonyl(Ci.-C6)alkyl; or (Cι-C6)alkylcarbonyl((Cι-C6)alkyl)n-, in which n is O or l The term "halogen atom" means a chlorine, bromine, iodine or fluorine atom. The monocyclic, bicyclic or tricyclic aromatic heterocyclic radicals preferably comprise one or more hetero atoms generally chosen from 0, S and N, optionally in oxidized form (in the case of S and N). Preferably, at least one of the monocycles constituting the heterocycle comprises from 1 to 4 endocyclic hetero atoms and better still from 1 to 3 hetero atoms. Preferably, the heterocycle consists of one or more monocycles, each of which is 5- to 8-membered. Examples of 5- to 8-membered monocyclic heteroaryls are especially pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isoxazole, isothiazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadiazole, triazole and thiadiazole. Examples of bicyclic heteroaryls in which each monocycles is 5- to 8- membered are chosen from indolizine, indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, benzothiazole, benzofurazane, benzothiofurazane, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridines, pyrazolotriazine (such as pyrazolo- 1 ,3,4-triazine), pyrazolopyrimidine and pteridine. Preferred heteroaryl radicals that may be mentioned include quinolyl, pyridyl, benzothiazolyl and triazolyl radicals. The tricyclic heteroaryls in which each monocycle is 5- to 8-membered are chosen, for example, from acridine, phenazine and carbazole. The term "alkylenediyl chain" means a divalent radical of linear or branched aliphatic hydrocarbon-based type derived from the alkyl groups defined above by stripping out a hydrogen atom. Preferred examples of alkylenediyl chains are chains -(CH2)k-, in which k represents an integer chosen from 2, 3, 4, 5 and 6 and >C(CH3)2 and -CH2-C(CH3)2-CH2- chains. The alkylenedioxy chains denote -O-Alk-0- chains, in which Alk represents linear or branched alkylene, it being understood that alkylene is as defined above for alkylenediyl. Preferred meanings of -O-Alk-O- are, for example, -0-C(CH3)2-O or -0-CH2-CH2-O-. The term "alkenylene" defines an unsaturated alkylene chain containing one or more ethylenic unsaturations, preferably one to three ethylenic unsaturations. Examples of alkylene chains are -CH=CH- or -CH=CH-CH=CH-. Examples of C3-C10 cycloalkyl radicals are especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or cyclodecyl radicals. Saturated or unsaturated, monocyclic 5- to 8-membered heterocycles are saturated, or unsaturated, derivatives of aromatic heterocycles. Mention may be made more particularly of morpholine, piperidine, thiazolidine, oxazolidine, tetrahydrothienyl, tetrahydrofuryl, pyrrolidine, isoxazolidine, imidazolidine or pyrazolidine. The term "alkynyl" means an aliphatic hydrocarbon-based group containing one or more unsaturations of acetylenic type. A preferred example is -CsC-. The compounds of the formula (I) that are preferred are those in which R represents a hydrogen atom, R1 and R2 being as defined previously, the optical isomers thereof, and also the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical. Another preferred group of compounds of the invention consists of the compounds for which: R1 represents a (C6-C-|8)aryl radical bearing a substituent G, itself comprising an optionally substituted (C6-Cι8)aryl radical and/or a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; and R2 is chosen from: • a (C6-Cι8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical. Another preferred group of compounds of the invention consists of the compounds for which: R1 represents an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; or alternatively fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and R2 is chosen from: • a (C6-Ci8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
Another preferred group of compounds of the invention consists of the compounds for which: R1 represents a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and R2 is chosen from: • a (C6-Cιs)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. Another preferred group of compounds of the invention consists of the compounds for which: R1 represents a (C6-Cι8)aryl radical bearing from two to five identical or different substituents G; and R2 is chosen from: • a (C6-C18)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. Compounds that are also preferred are those of the general formula
(I) for which: R2 represents a (C6-Cι8)aryl radical substituted by a (C6-Cι8)aryl radical, which is itself optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated, 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. Another preferred group consists of the compounds of the general formula (I) for which: R2 represents an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and R1 is chosen from: • an optionally substituted (C6-C18)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. Another preferred group consists of the compounds of the general formula (I) for which: R2 represents an optionally substituted biphenyl radical; and R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. Another preferred group consists of the compounds of the general formula (I) for which: R2 represents an optionally substituted halogenated biphenyl radical, preferably an optionally substituted 4'-halogenated biphenyl radical; and R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; R being as defined above, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases. The compounds that are also preferred are those of the general formula (I) for which, when R1 represents a substituted (C6-Cι0)aryl radical, the aryl nucleus is substituted by one or more radicals G chosen from: trifluoromethyl; a halogen atom; styryl; a monocyclic, bicyclic or tricyclic aromatic heterocyclic radical comprising one or more hetero atoms chosen from O, N and S; and optionally substituted by one or more radicals T as defined below; a group Het-CO-, in which Het represents an aromatic heterocyclic group as defined above, optionally substituted by one or more radicals T; a Cι-C6 alkylenediyl chain; a Ci-Cβ alkylenedioxy chain; amino; nitro; cyano; (C1-C10)- alkyl radical; (C2-C6)alkynyl radical; (Cι-Cιo)alkylcarbonyl radical; (Cι-Cι0)alkoxy- carbonyl-A- radical, in which A represents (Cι-C6)alkylene, (C2-C6)alkenylene radical or a bond; (C3-Cιo)cycloalkyl radical; trifluoromethoxy radical; di(Cι-Cιo)- alkylamino radical; (C1-C10)alkoxy(C1-Cι0)alkyl radical; (Ci-Cio)alkoxy radical; (C6-Ci8)aryl radical optionally substituted by one or more radicals T; (C6-Ci8)aryl(Ci-Cio)alkoxy-(CO)n- radical, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(CO)n- radical, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(CO)n-(C2-C6)alkenyl radical, in which n is 0 or 1 ; (C6-Cι8)arylthio radical, in which aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(Cι-Cι0)alkyl(CO)n-, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; a saturated or unsaturated, monocyclic 5- to 8-membered heterocycle comprising one or more hetero atoms chosen from O, N and S, optionally substituted by one or more radicals T; (C6-Cι8)arylcarbonyl radical optionally substituted by one or more radicals T; (C6-Ci8)arylcarbonyl-B-(CO)n- radical, in which n is 0 or 1 ; B represents (Ci-Ce)alkylene or (C2-C8)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryl-C-(CO)n- radical, in which n is 0 or 1 , C represents (Cι-Cβ)alkylene or (C2-Ce)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryl radical fused to a saturated or unsaturated heterocycle as defined above, optionally substituted by one or more radicals T; (C2-Cιo)alkynyl radical; T is chosen from a halogen atom; (C6-Cι8)aryl; (Cι-C6)alkyl; (Cι-C6)alkoxy; nitro; carboxyl; (CrC6)alkoxy- carboxyl; and T may represent oxo in the case where it substitutes a saturated or unsaturated heterocycle; or alternatively T represents (Cι-C6)alkoxy- carbonyl(Cι-C6)alkyl; or (Cι-C6)alkylcarbonyl((Cι-C6)alkyl)n-, in which n is 0 or 1. More particularly, the preferred compounds are those of the formula (I) chosen from: • (2S)-2-[4-(5-chlorothien-2-yl)phenoxy]-4-phenylbutanoic acid; • 2-{2-[3-(4-chlorophenyl)acryloyl]-4-methylphenoxy}-4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-2-yl)phenoxy]-4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-3-yl)phenoxy)-4-phenylbutanoic acid; • 4-(2-fluorophenyl)-2-[4-(2-methylthiazol-4-yl)phenoxy]butanoic acid; • 4-(4'-chlorobiphenyl-4-yl)-2-(4-nitrophenoxy)butanoic acid; • 4-(4-fluorophenyl)-2-[4-(2-methylthiazol-4-yl)phenoxy]butanoic acid; and • (2S)-2-(4-furan-2-ylphenoxy)-4-phenylbutanoic acid. The invention also relates to pharmaceutical compositions comprising a pharmaceutically effective amount of at least one compound of the formula (I) as defined above in combination with one or more pharmaceutically acceptable vehicles. These compositions can be administered orally in the form of tablets, gel capsules or granules with immediate release or controlled release, intravenously in the form of an injectable solution, transdermally in the form of an adhesive transdermal device, or locally in the form of a solution, cream or gel. A solid composition for oral administration is prepared by adding to the active principle a filler and, where appropriate, a binder, a disintegrating agent, a lubricant, a colorant or a flavour enhancer, and by forming the mixture into a tablet, a coated tablet, a granule, a powder or a capsule. Examples of fillers include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide, and examples of binders include poly(vinyl alcohol), poly(vinyl ether), ethylcellulose, methylcellulose, acacia, gum tragacanth, gelatine, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin. Examples of lubricants include magnesium stearate, talc, polyethylene glycol, silica and hardened plant oils. The colorant may be any of those permitted for used in medicaments. Examples of flavour enhancers include cocoa powder, mint in herb form, aromatic powder, mint in oil form, borneol and cinnamon powder. Obviously, the tablet or granule can be suitably coated with sugar, gelatine or the like. An injectable form comprising the compound of the present invention as active principle is prepared, where appropriate, by mixing the said compound with a pH regulator, a buffer agent, a suspension agent, a solubilizer, a stabilizer, an isotonic agent and/or a preserving agent, and by converting the mixture into a form for intravenous, subcutaneous or intramuscular injection, according to a standard process. Where appropriate, the injectable form obtained can be freeze-dried via a standard process. Examples of suspension agents include methylcellulose, polysorbate 80, hydroxyethylcellulose, acacia, powdered gum tragacanth, sodium carboxymethylcellulose and polyethoxylated sorbitan monolaurate. Examples of solubilizers include castor oil solidified with polyoxyethylene, polysorbate 80, nicotinamide, polyethoxylated sorbitan monolaurate and the ethyl ester of castor oil fatty acid. In addition, the stabilizer encompasses sodium sulfite, sodium metasulfite and ether, while the preserving agent encompasses methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol. The present invention also relates to the use of a compound of the formula (I) of the invention for the preparation of a medicament for the prevention of or treating dyslipidaemia, atherosclerosis and diabetes. The effective administration doses and posologies of the compounds of the invention, intended for the prevention or treatment of a disease, disorder or condition caused by or associated with modulation of PPAR activity, depends on a large number of factors, for example on the nature of the inhibitor, the size of the patient, the aim of the desired treatment, the nature of the pathology to be treated, the specific pharmaceutical composition used and the observations and the conclusions of the treating physician. For example, in the case of an oral administration, for example a tablet or a gel capsule, a possible suitable dosage of the compounds of the formula (I) is between about 0.1 mg/kg and about 100 mg/kg of body weight per day, preferably between about 0.5 mg/kg and about 50 mg/kg of body weight per day, more preferably between about 1 mg/kg and about 10 mg/kg of body weight per day and more preferably between about 2 mg/kg and about 5 mg/kg of body weight per day of active material. If representative of body weights of 10 kg and 100 kg are considered in order to illustrate the oral daily dosage range that can be used and as described above, suitable dosages of the compounds of the formula (I) will be between about 1-10 mg and 1000-10 000 mg per day, preferably between about 5-50 mg and 500-5000 mg per day, more preferably between about 10.0-100.0 mg and 100.0-1000.0 mg per day and even more preferably between about 20.0-200.0 mg and about 50.0-500.0 mg per day of active material comprising a preferred compound. These dosage ranges represent total amounts of active material per day for a given patient. The number of administrations per day at which a dose is administered can vary within wide proportions depending on pharmacokinetic and pharmacological factors, such as the half-life of the active material, which reflects its rate of catabolism and clearance, and also the minimum and optimum levels of the said active material, in blood plasma or in other bodily fluids, which are reached in the patient and which are required for therapeutic efficacy. Many other factors should also be taken into consideration when determining the number of daily administrations and the amount of active material that should be administered in a single dosage intake. Among these other factors, and not the least of which, is the individual response of the patient to be treated. The present invention also relates to a general process for the preparation of the compounds of the formula (I), by reaction of a compound of the formula (II) with an alcohol of the formula R1-OH, according to the following reaction scheme:
Figure imgf000021_0001
(Aa) : THF / PPh3 / DIAD / room temp. (Ab) : EtOH / KOH / H20 reflux in which reaction scheme R1 and R2 are as defined above for formula (I), R' represents R as defined above, with the exception of hydrogen, the compound (IR-) being the compound of the formula (I) in which R represents a C1-C10 alkyl radical, as defined above, and the compound (I0H) being the compound of the formula (I) in which R represents -H. THF means tetrahydrofuran. PPh3 means triphenylphosphine, DIAD means diisopropyl azodicarboxylate, "room temp." means room temperature, EtOH is ethanol and KOH is potassium hydroxide. The reaction step (Aa) is preferably performed in a polar aprotic solvent, such as a linear or cyclic ether of the type, such as diethyl ether, di- tert-butyl ether, diisopropyl ether or dimethoxyethane, or alternatively of the type, such as dioxane or tetrahydrofuran, tetrahydrofuran and dimethoxyethane being preferred. According to one preferred embodiment of the invention, the molar ratio of the compound of the formula (II) to the alcohol R1-OH ranges between 1 and 1.5, an approximately stoichiometric ratio of between 1 and 1.3 and preferably between 1 and 1.1 being desirable. So as to facilitate the reaction, it is desirable to and to the medium a coupling agent, such as a lower alkyl (i.e. a Ci-Cβ alkyl) azodicarboxylate, for example diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD). When it is present in the reaction medium, the coupling agent is incorporated into the medium in a proportion of from 0.9 to 5 molar equivalents and better still in a proportion of from 0.9 to 3 molar equivalents, for example in a proportion of from 0.9 to 2 molar equivalents, relative to the initial amount of compound of the formula (II). Preferably, it is also recommended to introduce a phosphine into the reaction medium, such as triphenylphosphine. In this case, the molar ratio of the triphenylphosphine to the compound of the formula (II) is preferably maintained between 0.9 and 5, for example between 0.9 and 3 and especially between 0.9 and 2. The reaction temperature generally ranges between -15°C and 60°C. In the above reaction scheme, the saponification reaction step (Ab) is optional, i.e. it is performed only in the case where the desired compound of the formula (I) is a carboxylic acid (R = H). In this case, the compounds of the formula (I) in which R represents
H can advantageously be obtained by saponification of the corresponding compounds of the formula (lR-). The saponification can be performed via the action of a base, such as a mineral base chosen from lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate and potassium carbonate.
The molar amount of base to be used generally ranges from 1 to 20 equivalents and preferably from 1 to 12 equivalents depending on the strength of the selected base. More particularly, in the case of lithium hydroxide (LiOH), it is preferred to incorporate from 8 to 12 equivalents of base relative to the amount of ester of the formula (I) present in the reaction medium. The reaction is preferably performed in a solvent of polar protic type and preferably in a mixture of lower (C1-C4) alkanol and water, such as a mixture of ethanol and water or of methanol and water. The reaction temperature advantageously ranges between 20°C and
120°C. According to another embodiment of the process according to the invention, the compounds of the formula (lG), which is a special case of the compounds of the formula (I) in which R1 represents an aryl radical substituted by a radical G as defined above, can be prepared according to the following reaction scheme:
Figure imgf000023_0001
(Ba) : CH3OCH2CH2OCH3 / Pd(PPh3)4 / Na2C03 / H20 (Bb) : EtOH / KOH / H20 / reflux in which reaction scheme: R2 is as defined above for formula (I) ; R' represents R, as defined above, with the exception of hydrogen; R11 represents R1, as defined above, bearing a group that is reactive with the derivative of the formula (IV) and chosen especially from a bromine or iodine atom and a CF3S03- radical, bromine and iodine being the preferred reactive groups; and - R12 represents R11, in which the group that is reactive with the derivative of the formula (IV) has been substituted by the radical G. As indicated in the above reaction schemes, the saponification step (Bb) is optional. The compounds of the formulae (IG, RO and (IG, H) form the set of compounds of the formula (IG), which is a special case of the compounds of the formula (I) in which R1 represents an aryl radical substituted by a radical G. Thus, the compounds of the formula (I) in which R1 represents aryl substituted by a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S, and optionally substituted by one or more radicals T as defined above, or alternatively in which R1 represents an aryl group optionally substituted by one or more radicals T, can be prepared by reaction of the corresponding compound of the formula (III) defined above with a compound of the formula (IV) defined in the above reaction scheme, in which G represents a monocyclic, bicyclic or tricyclic aromatic heterocyclic group comprising one or more hetero atoms chosen from O, N and S, and optionally substituted by one or more radicals T as defined above when R1, in the final compound, represents aryl substituted by such a heterocyclic group, or alternatively G represents aryl optionally substituted by one or more radicals T when, in the final compound, R1 represents aryl substituted by an aryl group, which is itself optionally substituted by one or more radicals T. Advantageously, from 1.5 to 5 equivalents and preferably from 1.5 to 3 equivalents of the compound of the formula (IV) are incorporated relative to the amount of compound of the formula (111) present in the reaction medium. This reaction is preferably performed in a polar aprotic solvent in the presence of a palladium 0 complex and a base. A linear or cyclic ether, such as those defined above is more particularly suitable as solvent. Dimethoxyethane is preferred. The base that will be used is any of the mineral bases mentioned above and advantageously sodium carbonate. For example, from 1.5 to 5 equivalents and preferably from 1.5 to 3 equivalents of base, relative to the amount of compound of the formula (III), can be introduced into the reaction medium. The amount of palladium 0 complex used is catalytic. Usually, from 0.001 to 1 equivalent and preferably from 0.01 to 0.1 equivalent of the said complex is used. An example of a palladium 0 complex that can be used is tetrakis(triphenylphosphine)palladium 0. The reaction temperature advantageously ranges between 50°C and
120°C and preferably between 70°C and 90°C. The compounds of the formula (I) can also be prepared according to a synthetic route using compounds grafted onto resin, for example of Wang bromo type, according to the following reaction scheme:
Figure imgf000025_0001
CH-CI-, r.t, 18 h in which scheme R1 and R2 are as defined for the general formula (I). In the above reaction scheme, caesium carbonate is added to a solution of α-hydroxy acid, in a solvent, for example a protic solvent, such as dimethylformamide, to which is then added a suspension of resin, so as to obtain the α-hydroxy acid derivative grafted onto resin. To this derivative is then added the alcohol R1-OH in the presence of a phosphine, such as 4,4-dimethyl-2-(triphenylphosphanyl)-1,2,5-thiadiazoli- dine. The reaction is performed, generally at room temperature, for a time that can range from one to several hours, for example about 18 hours. The compound is then detached from the resin, according to standard techniques, for example using trifluoroacetic acid, to give the carboxyiic acid obtained in the final step of the above reaction scheme. This carboxyiic acid is a special case of the compound of the formula (I) in which R represents hydrogen, and can optionally be readily converted into a compound of the formula (I) in which R has the definition indicated previously for all the compounds according to the invention, with the exception of hydrogen, via any method known per se. In the processes described above, it should be understood that the operating conditions can vary substantially depending on the various substituents present in the compounds of the formula (I) that it is desired to prepare. Such variations and adaptations are readily available to a person skilled in the art, for example from scientific reviews, the patent literature, Chemical Abstracts, and computer databases, including the Internet. Similarly, the starting materials are either commercially available or are available via syntheses that a person skilled in the art can readily find, for example in the various publications and databases described above. The optical isomers of the compounds of the formula (I) can be obtained, on the one hand, via standard techniques for separating and/or purifying isomers, known to those skilled in the art, from the racemic mixture of the compound of the formula (I). The optical isomers can also be obtained directly via stereoselective synthesis of an optically active starting compound. The following reaction scheme gives an illustration of an example of a stereoselective synthesis using an optically active starting compound:
Figure imgf000026_0001
EXAMPLES
The examples that follow illustrate the present invention without limiting it in any way. In these examples and in the proton nuclear magnetic resonance (300 MHz NMR) data, the following abbreviations have been used: s for singlet, d for doublet, t for triplet, q for quartet, o for octet and m for complex multiplet. The chemical shifts δ are expressed in ppm. "MW" means molecular weight and "m.p." means "melting point".
Example 1: Process for the preparation of methyl 2-[4-(2-methyl-1 ,3- thiazol-4-yl)phenoxy]-4-(4-fluorophenyl)butanoate 6.7 mmol of diisopropyl azodicarboxylate dissolved in 5 ml of toluene are added dropwise over 45 minutes to a suspension, under a nitrogen atmosphere, of 7 mmol of methyl 4-(4-fluorophenyl)-2-hydroxybutanoate, 6.3 mmol of 4-(2-methyl-1 ,3-thiazol-4-yl)phenol and 6.9 mmol of triphenylphosphine in 50 ml of toluene, heated to 54°C ± 3°C. The solution obtained is maintained at this temperature for 1 hour, cooled to room temperature and stirred overnight. The insoluble material formed is filtered off by suction, washed with 5 ml of ice-cold toluene and then discarded. The filtrate is evaporated under vacuum and the viscous residue is chromatographed on a column of silica, eluting with 90/10 heptane/ethyl acetate. A small amount of triphenylphosphine is recovered in the first fraction. The expected product constitutes the second fraction, in the form of a pale yellow oil that crystallizes. Yield: 52%.
Example 2: Process for the preparation of 2-[4-(2-methyl-1,3-thiazol-4- yl)phenoxy]-4-(4-fluorophenyl)butanoic acid (Example 145 of the table)
36 ml (36 mmol) of aqueous 1 M lithium hydroxide monohydrate solution are added dropwise over 30 minutes to a solution of 3.6 mmol of the compound obtained in Example 1 , in 100 ml of methanol. The reaction is slightly exothermic. The mixture is then stirred for 2 hours at room temperature, after which the solvents are evaporated off to dryness under vacuum. The white solid residue obtained is taken up in 200 ml of water. The resulting suspension is stirred for 30 minutes and then acidified with 1/2 hydrochloric acid (HCI). Stirring is continued for 30 minutes and the medium is then extracted with ethyl acetate, with continued stirring until dissolution is complete. After separation of the phases by settling, the organic phase is dried over sodium sulfate and then evaporated to dryness under vacuum, to give the expected product in the form of a white solid melting above 260°C. Yield: 95%. M.p.: > 260°C 1H NMR (300 MHz; DMSO-d6): 1.90-2.23 (2H, m); 2.59-2.89 (2H, m); 2.68 (3H, s); 4.21-4.39 (1H, m); 6.72-7.30 (6H, m); 7.62-7.84 (3H, m).
Example 3: Process for the preparation of ethyl (2S)-2-[4-(furan-2- yl)phenoxy]-4-phenylbutanoate
0.024 mmol of tetrakis(triphenylphosphine)palladium, 12.3 mmol of 2- furanboronic acid and 7.5 ml of 2 M sodium carbonate solution are added to a solution of 6.15 mmol of ethyl (2S)-2-(4-bromophenoxy)-4-phenylbutanoate in 25 ml of dimethoxyethane. The mixture is refluxed for 2 hours. After cooling to room temperature, the mixture is taken up in water and extracted with ethyl acetate. The organic phase is dried over sodium sulfate (Na2S04) and then evaporated to dryness under vacuum. 2.6 g of a brown oil are obtained. This oil is chromatographed with a 9/1 heptane/ethyl acetate mixture as eluent. 1.5 g of an oil that crystallizes are obtained. Yield: 68%. Example 4: Process for the preparation of (2S)-2-[4-(furan-2- yl)phenoxy]-4-phenyibutanoic acid (Example 22 of the table) 21.5 mmol of potassium hydroxide are added to a solution of
4.3 mmol of ethyl (2S)-2-(4-furan-2-ylphenoxy)-4-phenylbutanoate, obtained in the preceding example, in 30 ml of ethanol. The mixture is refluxed for 30 minutes, 15 ml of water are added and refluxing is continued for 3 hours 30 minutes. After cooling to room temperature, the ethanol is evaporated off under vacuum. The product is taken up in water and washed with ether. The aqueous phase is acidified with 10% hydrochloric acid. A white precipitate forms, which is extracted with ethyl acetate. The organic phase is dried over sodium sulfate and evaporated under vacuum. 1.2 g of a beige-coloured solid, that recrystallizes from a hexane/ethyl acetate mixture to give 1 g of a solid melting at 140-142°C, are obtained. Yield: 72.5%. 1H NMR (300 MHz; CDCI3): 2.15-2.50 (2H, m); 2.73-3.05 (2H, m); 4.55-4.75 (1H, m); 6.32-6.63 (2H, m); 6.79-7.04 (2H, m); 7.07-7.76 (8H, m).
Example 5: Process for the preparation of (E)-2-[4-(2-ethoxycarbonyl- vinyl)-2-methoxyphenoxy]-4-phenylbutanoic acid (Example 66 of the table)
A 20% solution of caesium carbonate in water (23 ml, 14.4 mmol) is added to a solution of 2-hydroxy-4-phenylbutanoic acid (7 g, 3.8 mmol) in methanol (200 ml). After stirring for 10 minutes, the solvents are evaporated off and the residue is taken up in toluene, which is then evaporated off. The residue is taken up in dimethylformamide (DMF) (125 ml), and is then added to a suspension of resin (23.7 g, 18 mmol) in DMF (125 ml). The reaction is stirred for 18 hours at 60°C. The resin is then washed several times with tetrahydrofuran (THF) (3 x 150 ml, 2 minutes), 1/1 THF/H20 (3 * 150 ml, 2 minutes), methanol (3 x 150 ml, 2 minutes), dichloromethane (3 x 150 ml, 2 minutes) and methanol (3 x 150 ml, 2 minutes). The resin is dried under vacuum at 50°C. A solution of ethyl (E)-3-(4-hydroxy-2-methoxy)phenylpent-2-enoate (1 mmol) in dichloromethane (2 ml) is added to grafted resin (150 mg, 0.1 mmol). A solution of 4,4-dimethyl-2-(triphenylphosphanyl)-1 ,2,5-thiadia- zo-li-dine (1 mmol) in dichloromethane (8 ml) is then added and the suspension is stirred at room temperature for 18 hours. The resin is filtered off and washed with DMF (5 ml), 50/50 DMF/H2O (5 ml), methanol (2 5 ml) and 80/20 dichloromethane/dichloroethane (DCM/DCE) (3 x 5 ml). The resin is then treated with 20/80 trifluoroacetic acid/dichloromethane (TFA/DCM) solution for 15 minutes. The resin is filtered off and washed with dichloromethane (2 5 ml). The filtrate is evaporated to give 1.9 mg of an oil, which is purified by preparative LCMS (liquid chromatography/mass spectrometry). Mass spectrometrv: ES-: 383.3. The examples that follow are obtained according to procedures similar to those that have just been presented in the preceding examples.
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000056_0002
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
RESULTS
The activity of the compounds of the invention leading to a hypolipidaemiant and hypoglycaemiant effect was demonstrated in vitro and in vivo by performing the following tests. Demonstration of the in vitro activity The measurement of the PPAR activation was performed according to a technique described by Lehmann et al. (J. Biol. Chem., 270, (1995), 12953-12956). CV-1 cells (monkey kidney cells) are co-transfected with an expression vector for the chimeric proteins PPARα-Gal4 or PPARγ-Gal4 and with a "reporter" plasmid that allows the expression of the luciferase gene placed under the control of a promoter comprising Gal4 response elements. The cells are plated into 96-well microplates and co-transfected using a commercial reagent with the reporter plasmid (pG5-tk-pGL3) and the expression vector for the chimeric protein (PPARα-Gal4 or PPARγ-Gal4). After incubating for 4 hours, whole culture medium (comprising 10% foetal calf serum) is added to the wells. After 24 hours, the medium is removed and replaced with whole medium comprising the test products (50 μM final). The products are left in contact with the cells for 18 hours. The cells are then lysed and the luciferase activity is measured using a luminometer. A PPAR activation factor can then be calculated by means of activation of the expression of the reporter gene induced by the product (relative to the control cells that have not received any product). By way of example, the compound of Example 18 at a concentration of 50 μM, activates the chimeric protein PPARα-Gal-4 by a factor of 16, and the chimeric protein PPARγ-Gal4 by a factor of 41. In the absence of the binding domain for the PPAR α or γ ligand (vector expressing Gal4 alone), the luciferase activity measured in the presence of this product is zero. Demonstration of the in vivo activity The antidiabetic and hypolipidaemiant activity of the compounds according to the invention was determined orally on db/db mice. 15-week-old db/db mice are treated orally for 15 days with the compound of Example 18 (20 mg/kg/day). Each group studied comprises seven animals. After treatment for 15 days, retro-orbital samples are taken under mild anaesthesia and after fasting for four hours. The following parameters were measured: Assay of the glycaemia (glucose oxidase) and of the lipid parameters on the sera at D15 (COBAS): triglycerides, total cholesterol (CHOL), HDL cholesterol (HDL-C) and free fatty acids (FFA) (BioMerieux and Waco Chemicals assay kit). The results obtained are given in the table below. The measurements reported represent mean values ± standard error.
Figure imgf000132_0001
% var.: percentage of variation versus control. Mann-Whitney test: * : p < 0.05 versus control ** : p < 0.01 versus control These results demonstrate the antidiabetic and hypolipidaemiant activity of the compounds of the invention on triglycerides and free fatty acids. The marked increase in the level of HDL cholesterol with these same compounds should be noted.

Claims

1. Compound of the formula (I):
Figure imgf000133_0001
in which:
R is chosen from a hydrogen atom and a C1-C10 alkyl radical; R1 and R2, which may be identical or different, are chosen such that: A.- either: R1 is chosen from: • a (C6-Cι8)aryl radical bearing from two to five identical or different substituents G; • a (C6-C18)aryl radical bearing a substituent G, itself comprising an optionally substituted (C6-Ci8)aryl radical and/or a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; • an optionally substituted (C6-Cι8)aryl radical, fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Ci8)aryl radical, fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; and, in this case, R2 is chosen from: • a (C6-Ci8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; B.- or: R2 is chosen from: • a (C6-Cιβ)aryl radical substituted by a (C6-C-i8)aryl radical, which is itself optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; and, in this case, R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Ciδ)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus bearing at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from oxygen, nitrogen and sulfur; the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical.
2. Compound according to Claim 1, in which R represents a hydrogen atom, R1 and R2 being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical.
3. Compound according to Claim 1, in which R1 represents a (C6-Cιs)aryl radical bearing a substituent G, itself comprising an optionally substituted (C6-C 8)aryl radical and/or a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and R2 is chosen from: • a (C6-Cι8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1, the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases, with the restriction that when R2 represents a phenyl radical not substituted by an aromatic or heteroaromatic radical, then R1 cannot represent a phenyl radical that is itself substituted by a phenyl or naphthyl radical.
4. Compound according to Claim 1 , in which R1 represents an optionally substituted (C6-Ci8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; or alternatively fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and R2 is chosen from: • a (C6-Cι8)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
5. Compound according to Claim 1 , in which R1 represents a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from 0, N and S; and R2 is chosen from: • a (C6-Ciδ)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
6. Compound according to Claim 1 , in which R1 represents a (C6- Cιs)aryl radical bearing from two to five identical or different substituents G; and R2 is chosen from: • a (C6-C18)aryl radical, which is optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and • an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
7. Compound according to Claim 1 , in which R2 represents a (CQ- Cis)aryl radical substituted by a (C6-Cι8)aryl radical, which is itself optionally substituted and/or optionally fused to a saturated or unsaturated 5- to 8- membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from O, N and S, the said nucleus itself being optionally substituted; and R1 is chosen from: • an optionally substituted (C6-C-|8)aryl radical fused to a saturated or unsaturated, 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
8. Compound according to Claim 1 , in which R2 represents an optionally substituted 5- to 8-membered monocyclic aromatic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; and R1 is chosen from: • an optionally substituted (C6-Ci8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cie)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
9. Compound according to Claim 1 , in which R2 represents an optionally substituted biphenyl radical; and R1 is chosen from: • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (C6-Cι8)aryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
10. Compound according to Claim 1 , in which R2 represents an optionally substituted halogenated biphenyl radical, preferably an optionally substituted 4'-halogenated biphenyl radical; and R1 is chosen from: • an optionally substituted (C6-Ci8)aryl radical fused to a saturated or unsaturated 5- to 8-membered monocyclic or polycyclic nucleus optionally containing one or more hetero atoms chosen from oxygen and sulfur, the said nucleus itself being optionally substituted; • an optionally substituted (Cβ-Cisjaryl radical fused to a saturated or unsaturated 6- to 8-membered monocyclic or polycyclic nucleus comprising at least one nitrogen atom as hetero atom, the said nucleus itself being optionally substituted; and • a saturated, unsaturated or aromatic, optionally substituted 5- to 8-membered monocyclic heterocyclic radical containing one or more hetero atoms chosen from O, N and S; R being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
11. Compound according to Claim 1 , in which, when R1 represents a substituted (C6-Cι0)aryl radical, the aryl nucleus is substituted by one or more radicals G chosen from: trifluoromethyl; a halogen atom; styryl; a monocyclic, bicyclic or tricyclic aromatic heterocyclic radical comprising one or more hetero atoms chosen from O, N and S; and optionally substituted by one or more radicals T as defined below; a group Het-CO-, in which Het represents an aromatic heterocyclic group as defined above, optionally substituted by one or more radicals T; a C-ι-C6 alkylenediyl chain; a C-ι-C6 alkylenedioxy chain; amino; nitro; cyano; (C1-C10)- alkyl radical; (C2-C6)alkynyl radical; (Cι-C10)alkylcarbonyl radical; (C1-C10)- alkoxycarbonyl-A- radical, in which A represents (C-i-CβJalkylene, (C2-Cδ)- alkenylene radical or a bond; (C3-C-to)cycloalkyl radical; trifluoromethoxy radical; di(Cι-Cιo)alkylamino radical;
Figure imgf000141_0001
radical; (Cι-Cι0)alkoxy radical; (C6-Cis)aryl radical optionally substituted by one or more radicals T; (C6-Cι8)aryl(Cι-Cιo)alkoxy-(CO)n- radical, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; (C6-Ci8)aryloxy(CO)n- radical, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; (C6-C18)aryloxy(CO)n-(C2-C6)alkenyl radical, in which n is 0 or 1; (C6-C-|8)arylthio radical, in which aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryloxy(Cι-Cιo)alkyl(CO)n-, in which n is 0 or 1 and in which aryl is optionally substituted by one or more radicals T; a saturated or unsaturated, monocyclic 5- to 8-membered heterocycle comprising one or more hetero atoms chosen from O, N and S, optionally substituted by one or more radicals T; (C6-Cι8)arylcarbonyl radical optionally substituted by one or more radicals T; (C6-Cι8)arylcarbonyl-B-(CO)n- radical, in which n is 0 or 1 ; B represents (Cι-C6)alkylene or (C2-C6)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryl-C-(CO)n- radical, in which n is 0 or 1, C represents (Cι-C6)alkylene or (C2-C6)alkenylene and aryl is optionally substituted by one or more radicals T; (C6-Cι8)aryl radical fused to a saturated or unsaturated heterocycle as defined above, optionally substituted by one or more radicals T; (C2-Cιo)alkynyl radical; T is chosen from a halogen atom; (C6-Cι8)aryl; (CrC6)alkyl; (Cι-C6)alkoxy; nitro; carboxyl; (Cι-C6)alkoxy- carboxyl; and T may represent oxo in the case where it substitutes a saturated or unsaturated heterocycle; or alternatively T represents (CrCβJalkoxycarbonyl- (Cι-C6)alkyl; or (Cι-C6)alkylcarbonyl((Cι-C6)alkyl)n-, in which n is 0 or 1 ; R and R2 being as defined in Claim 1 , the optical isomers thereof, and the pharmaceutically acceptable addition salts thereof with acids or bases.
12. Compound according to Claim 1 , chosen from: • (2S)-2-[4-(5-chlorothien-2-yl)phenoxy]-4-phenylbutanoic acid; • 2-{2-[3-(4-chlorophenyl)acryloyl]-4-methylphenoxy}-4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-2-yl)phenoxy]-4-phenylbutanoic acid; • (2S)-2-[4-(benzo[b]thiophen-3-yl)phenoxy)-4-phenylbutanoic acid; • 4-(2-fluorophenyl)-2-[4-(2-methylthiazol-4-yl)phenoxy]butanoic acid; • 4-(4'-chlorobiphenyl-4-yl)-2-(4-nitrophenoxy)butanoic acid; • 4-(4-fluorophenyl)-2-[4-(2-methylthiazol-4-yl)phenoxy]butanoic acid; and • ' (2S)-2-(4-furan-2-ylphenoxy)-4-phenylbutanoic acid.
13. Process for the preparation of a compound according to any one of the preceding claims, by reaction of a compound of the formula (II) with an alcohol of the formula R1-OH according to the following reaction scheme:
Figure imgf000143_0001
(Aa) : THF / PPh3 / DIAD / room temp. (Ab) : EtOH / KOH / H20 reflux in which reaction scheme R1 and R2 are as defined in Claim 1 , R' represents R as defined above, with the exception of hydrogen, the compound (IR<) being the compound of the formula (I) in which R represents a
C1-C10 alkyl radical, as defined above, and the compound (IOH) being the compound of the formula (I) in which R represents -H.
14. Process for the preparation of a compound according to Claim 1 , in which R1 represents an aryl radical substituted by a radical G, according to the following reaction scheme, the first step being performed in a polar aprotic solvent in the presence of a palladium 0 complex and a base; the second step being an optional saponification reaction:
Figure imgf000143_0002
(Ba) : CH3OCH2CH2OCH3 / Pd(PPh3)4 / Na2C03 / H20 (Bb) : EtOH / KOH / H20 / reflux in which reaction scheme: - R2 is as defined in Claim 1 ; - R' represents R, as defined in Claim 1 , with the exception of hydrogen; - R11 represents R1, as defined in Claim 1 , bearing a group that is reactive with the derivative of the formula (IV) and chosen especially from a bromine or iodine atom and a CF3S03- radical, bromine and iodine being the preferred reactive groups; and R12 represents R1 , in which the group that is reactive with the derivative of the formula (IV) has been substituted by the radical G.
15. Process for the preparation of a compound according to Claim 1 , using compounds grafted onto resin, according to the following reaction scheme:
Figure imgf000144_0001
CH2CI2, r.t., 18 h in which scheme R1 and R2 are as defined in Claim 1 , this process comprising the steps of grafting a resin onto an α- hydroxy acid, which is then placed in contact with an alcohol of the formula R1-OH, R1 being as defined for the general formula (I), in the presence of a phosphine, the reaction being performed, at room temperature, for a time that may range from one to several hours, the resin then being detached from the substrate to give the compound of the formula (I) in which R represents hydrogen, which compound can be optionally converted into a compound of the formula (I) in which R is as defined in the general formula (I), with the exception of hydrogen.
16. Pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound according to any one of Claims 1 to 12, or obtained via a process according to any one of Claims 13 to 15, in combination with one or more pharmaceutically acceptable vehicles.
17. Use of a compound of the formula (I) according to any one of
Claims 1 to 12 or obtained via a process according to any one of Claims 13 to 15, for the preparation of a medicament for the prevention of or treating dyslipidaemia, atherosclerosis and diabetes.
PCT/EP2005/003607 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof WO2005105764A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK05729043.9T DK1742927T3 (en) 2004-05-03 2005-04-06 Butanonic acid derivatives, processes for their preparation, pharmaceutical compositions comprising them, and pharmaceutical applications thereof
SI200531318T SI1742927T1 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
CA2565184A CA2565184C (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
AT05729043T ATE503749T1 (en) 2004-05-03 2005-04-06 BUTTERIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THERAPEUTIC USES THEREOF
US11/579,362 US7678831B2 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
DE602005027194T DE602005027194D1 (en) 2004-05-03 2005-04-06 BUTTERIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THERAPEUTIC APPLICATIONS THEREOF
AU2005238143A AU2005238143B2 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
JP2007511903A JP5295560B2 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, methods for their preparation, pharmaceutical compositions containing them and therapeutic uses thereof
EP05729043A EP1742927B1 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
PL05729043T PL1742927T3 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404711A FR2869615B1 (en) 2004-05-03 2004-05-03 BUTANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THERAPEUTIC APPLICATIONS THEREOF
FR0404711 2004-05-03

Publications (1)

Publication Number Publication Date
WO2005105764A1 true WO2005105764A1 (en) 2005-11-10

Family

ID=34945568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003607 WO2005105764A1 (en) 2004-05-03 2005-04-06 Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof

Country Status (16)

Country Link
US (1) US7678831B2 (en)
EP (1) EP1742927B1 (en)
JP (1) JP5295560B2 (en)
AR (1) AR050154A1 (en)
AT (1) ATE503749T1 (en)
AU (1) AU2005238143B2 (en)
CA (1) CA2565184C (en)
CY (1) CY1111574T1 (en)
DE (1) DE602005027194D1 (en)
DK (1) DK1742927T3 (en)
ES (1) ES2364150T3 (en)
FR (1) FR2869615B1 (en)
PL (1) PL1742927T3 (en)
PT (1) PT1742927E (en)
SI (1) SI1742927T1 (en)
WO (1) WO2005105764A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041197A1 (en) * 2004-10-14 2006-04-20 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
WO2008040057A1 (en) * 2006-10-04 2008-04-10 Bionomics Limited Novel benzofuran potassium channel blockers and uses thereof
FR2909379A1 (en) * 2006-11-30 2008-06-06 Servier Lab New quinoline derivatives are aldose reductase inhibitors useful to treat and/or prevent e.g. hyperglycemia, dyslipidemia, insulin resistance, glucose intolerance, diabetes, kidney disease, retinopathies or obesity
WO2008108735A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
WO2010037127A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
WO2010070076A1 (en) * 2008-12-19 2010-06-24 Crystax Pharmaceuticals, S.L. Alkanoic acid derivatives and their therapeutic use as hdac inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395146B1 (en) * 2011-02-09 2014-05-16 부산대학교 산학협력단 New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof
CN108440278B (en) * 2018-03-07 2021-01-12 中国计量大学 Dicarboxy chalcone compound and its application in preparing anti-inflammatory medicine
CN109806251A (en) * 2019-03-04 2019-05-28 清华大学 The application of 3-hydroxybutyrate and its derivative in the product for preparing antiatherosclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100398A1 (en) * 2001-06-07 2002-12-19 Wyeth Combination of a ptpase inhibitor and an ace inhibitor
WO2004019869A2 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378582A (en) * 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
JPS64550A (en) * 1987-02-05 1989-01-05 Konica Corp Thermodeveloping photosensitive material
JP2771604B2 (en) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 Novel alkanoic acid derivatives as herbicides and their active ingredients
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
JP2001261612A (en) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc Catecholpropionic acid derivative and nuclear receptor agonist containing the same as active ingredient
US20040248849A1 (en) * 2001-06-28 2004-12-09 Potlapally Rajender Kumar 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation
KR20050058412A (en) * 2002-09-02 2005-06-16 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 Method of colouring porous material
WO2004099168A2 (en) * 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100398A1 (en) * 2001-06-07 2002-12-19 Wyeth Combination of a ptpase inhibitor and an ace inhibitor
WO2004019869A2 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041197A1 (en) * 2004-10-14 2006-04-20 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
AU2007304880B2 (en) * 2006-10-04 2012-10-11 Bionomics Limited Novel benzofuran potassium channel blockers and uses thereof
WO2008040057A1 (en) * 2006-10-04 2008-04-10 Bionomics Limited Novel benzofuran potassium channel blockers and uses thereof
AU2007304880B9 (en) * 2006-10-04 2012-11-08 Bionomics Limited Novel benzofuran potassium channel blockers and uses thereof
FR2909379A1 (en) * 2006-11-30 2008-06-06 Servier Lab New quinoline derivatives are aldose reductase inhibitors useful to treat and/or prevent e.g. hyperglycemia, dyslipidemia, insulin resistance, glucose intolerance, diabetes, kidney disease, retinopathies or obesity
WO2008081096A2 (en) * 2006-11-30 2008-07-10 Les Laboratoires Servier Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents
WO2008081096A3 (en) * 2006-11-30 2008-08-21 Servier Lab Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents
US8785681B2 (en) 2007-03-08 2014-07-22 Albireo Ab 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
EP2125711A1 (en) * 2007-03-08 2009-12-02 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
US9181181B2 (en) 2007-03-08 2015-11-10 Albireo Ab 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
KR101558005B1 (en) * 2007-03-08 2015-10-06 알비레오 에이비 2--3- 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
EP2125711A4 (en) * 2007-03-08 2011-11-09 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
WO2008108735A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
WO2010037127A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
EP2342188A4 (en) * 2008-09-29 2012-06-06 Sirtris Pharmaceuticals Inc Chromenone analogs as sirtuin modulators
US8987258B2 (en) 2008-09-29 2015-03-24 Christopher Oalmann Chromenone analogs as sirtuin modulators
EP2342188A1 (en) * 2008-09-29 2011-07-13 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
KR20110063573A (en) * 2008-09-29 2011-06-10 서트리스 파마슈티컬즈, 인코포레이티드 Chromenone analogs as sirtuin modulators
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
KR101679089B1 (en) 2008-09-29 2016-11-23 서트리스 파마슈티컬즈, 인코포레이티드 Chromenone analogs as sirtuin modulators
WO2010070076A1 (en) * 2008-12-19 2010-06-24 Crystax Pharmaceuticals, S.L. Alkanoic acid derivatives and their therapeutic use as hdac inhibitors

Also Published As

Publication number Publication date
PT1742927E (en) 2011-07-04
FR2869615A1 (en) 2005-11-04
JP2007536291A (en) 2007-12-13
US7678831B2 (en) 2010-03-16
DK1742927T3 (en) 2011-06-27
ATE503749T1 (en) 2011-04-15
DE602005027194D1 (en) 2011-05-12
CA2565184A1 (en) 2005-11-10
EP1742927A1 (en) 2007-01-17
SI1742927T1 (en) 2011-07-29
AU2005238143B2 (en) 2011-02-03
PL1742927T3 (en) 2011-08-31
AR050154A1 (en) 2006-10-04
US20080032982A1 (en) 2008-02-07
EP1742927B1 (en) 2011-03-30
ES2364150T3 (en) 2011-08-25
CY1111574T1 (en) 2015-10-07
JP5295560B2 (en) 2013-09-18
AU2005238143A1 (en) 2005-11-10
FR2869615B1 (en) 2007-11-16
CA2565184C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
EP1742902B1 (en) Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
EP1742927B1 (en) Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
EP1742903B1 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
AU2005324904B2 (en) Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
US7863328B2 (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
EP1412326A1 (en) Butyric acid derivatives
AU2002355631A1 (en) Butyric acid derivatives
US20080194608A1 (en) 6-Phenylhex-5-Enoic Acid Derivatives, Process for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005729043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2565184

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11579362

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2007511903

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005238143

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005238143

Country of ref document: AU

Date of ref document: 20050406

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005238143

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005729043

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11579362

Country of ref document: US